ArticleCureus2025
Pulmonary Coccidioidomycosis in a Ruxolitinib-Treated Polycythemia Vera Patient: A Case Study and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi.Antimicrobial agents and chemotherapy · 2026Review
- Primary Cutaneous Coccidioidomycosis Presenting on the Leg of an Immunocompetent Patient: A Case Report.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report explores the epidemiology and clinical implications of coccidioidomycosis (Valley fever), with a focus on cases involving the immunosuppressive agent ruxolitinib (RUX) in patients with polycythemia vera (PV). The incidence of coccidioidomycosis has increased in the past decade in endemic regions, particularly in immunocompromised individuals. RUX, a Janus-associated kinase 1/2 (JAK1/2) inhibitor used in PV treatment, has been associated with various infections, but its link to coccidioidomycosis remains underexplored. We present a rare case of coccidioidomycosis in a PV patient receiving RUX, highlighting the potential risks associated with this therapy. Our analysis suggests a possible increased risk of coccidioidomycosis in RUX-treated patients, especially in endemic areas, which is supported by retrospective cohort data. This case underscores the importance of heightened vigilance and consideration of prophylactic measures in patients receiving RUX, particularly in regions where coccidioidomycosis is prevalent. Understanding these associations can inform clinical management strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.